England starts funding tirzepatide in specialist weight management services

Starting March 24, 2025, England's integrated care boards (ICBs) must cover the cost of tirzepatide (Mounjaro) for obesity in NHS specialist weight management services for any adult who meets the eligibility criteria in NICE technology appraisal TA1026, provided a prescribing clinician approves the treatment ^[1]. The date falls 90 days after NICE published its final guidance ^[1].

Under TA1026, adults qualify if they have an initial body mass index of at least 35 kg/m2 and at least one weight-related health condition, and use the drug alongside a reduced-calorie diet and increased physical activity. A lower BMI threshold, usually reduced by 2.5 kg/m2, applies to people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds ^[1]. Tirzepatide is a dual GIP/GLP-1 receptor agonist, and it carries Black Triangle status in the UK, a designation that signals extra safety monitoring after launch ^[1].

NHS England estimated that 3.4 million people would be eligible under those criteria ^[1]. Because of that scale, NHS England filed a funding variation request with NICE on behalf of NHS providers and ICBs, asking for more time to comply. NICE's Guidance Executive accepted the request ^[1].

The result is a staged rollout. Funding in specialist weight management services covers the full eligible population from March 2025, but funding in primary care settings begins later, from June 23, 2025, 180 days after final guidance publication, and only for prioritized groups on a phased basis ^[1]. NICE recommended identifying a cohort of about 220,000 people over the first three years of implementation, from 2025 to 2028 ^[1]. The full eligible population is meant to have access within a maximum of 12 years, with prioritization led by clinical need ^[1]. NHS England said the initial period will be used to evaluate service models and build primary care capacity ^[1].

The guidance also lays out the scale of the problem it is meant to address. In England, 29% of adults live with obesity and 64% live with overweight or obesity, according to NHS England. Obesity costs the NHS about £11.4 billion a year, and wider societal costs such as lost productivity are estimated at £74.3 billion a year ^[1].

Why it matters for patients

A funding mandate and actual access are different things. In England, the March 2025 requirement applies to hospital-based specialist weight management services, which are referral-based and limited in capacity, while the much larger primary care rollout is deliberately capped and sequenced ^[1]. That means most of the 3.4 million people estimated to be eligible will not get NHS-funded tirzepatide soon, and the guidance sets a horizon of up to 12 years for full access ^[1].

NHS England states that eligibility has to be phased because of system capacity, workforce readiness and resource availability, and that the priority order should follow clinical need ^[1]. The practical effect is that a prescription may depend less on whether someone meets the BMI and comorbidity criteria than on where they are in the queue.

None of this changes U.S. insurance coverage, FDA labeling or pharmacy pricing for tirzepatide. Those are governed by separate U.S. rules and were not addressed in the guidance ^[1]. What the English plan shows is a template other public payers could follow: a funder accepting the drug's benefits while stretching the timeline for paying for it.

What happens next

June 23, 2025 is the date ICBs became required to fund tirzepatide for obesity in primary care settings, on a phased, prioritized basis, alongside other treatment options ^[1]. The three-year cohorting plan runs from 2025 to 2028, scaling to roughly 220,000 patients, after which access is meant to widen toward the full eligible group within 12 years ^[1]. The specific order of priority cohorts in primary care, and how quickly each stage will open, has not been disclosed in this guidance ^[1].